Discounted Cash Flow
PTC Therapeutics, Inc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $82.7m | $-142.1m | $-105.3m | -171.8% | $-4.17 |
| 2017 | $194.4m (135.0%) | $-79.0m (44.4%) | $-13.2m (87.5%) | -40.6% (76.3%) | $-2.02 (51.6%) |
| 2018 | $264.7m (36.2%) | $-128.1m (-62.1%) | $-34.7m (-163.9%) | -48.4% (-19.0%) | $-2.75 (-36.1%) |
| 2019 | $307.0m (16.0%) | $-251.6m (-96.4%) | $-112.4m (-223.6%) | -82.0% (-69.4%) | $-4.27 (-55.3%) |
| 2020 | $380.8m (24.0%) | $-438.2m (-74.2%) | $-211.9m (-88.5%) | -115.1% (-40.4%) | $-6.64 (-55.5%) |
| 2021 | $538.6m (41.4%) | $-523.9m (-19.6%) | $-279.5m (-31.9%) | -97.3% (15.5%) | $-7.43 (-11.9%) |
| 2022 | $698.8m (29.7%) | $-559.0m (-6.7%) | $-388.7m (-39.0%) | -80.0% (17.8%) | $-7.79 (-4.8%) |
| 2023 | $937.8m (34.2%) | $-626.6m (-12.1%) | $-186.9m (51.9%) | -66.8% (16.5%) | $-8.37 (-7.4%) |
| 2024 | $806.8m (-14.0%) | $-363.3m (42.0%) | $-114.2m (38.9%) | -45.0% (32.6%) | $-4.73 (43.5%) |
| 2025 | $1.7b (114.5%) | $682.6m (287.9%) | $702.3m (715.1%) | 39.4% (187.6%) | $8.58 (281.4%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.